Cullinan Therapeutics (CGEM) Enterprise Value (2020 - 2023)
Historic Enterprise Value for Cullinan Therapeutics (CGEM) over the last 4 years, with Q3 2023 value amounting to -$868.0 million.
- Cullinan Therapeutics' Enterprise Value rose 454.32% to -$868.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$868.0 million, marking a year-over-year increase of 454.32%. This contributed to the annual value of -$467.3 million for FY2022, which is 6110.02% down from last year.
- According to the latest figures from Q3 2023, Cullinan Therapeutics' Enterprise Value is -$868.0 million, which was up 454.32% from -$841.8 million recorded in Q2 2023.
- Over the past 5 years, Cullinan Therapeutics' Enterprise Value peaked at -$208.9 million during Q4 2020, and registered a low of -$909.3 million during Q3 2022.
- Over the past 4 years, Cullinan Therapeutics' median Enterprise Value value was -$606.1 million (recorded in 2022), while the average stood at -$592.8 million.
- In the last 5 years, Cullinan Therapeutics' Enterprise Value crashed by 16020.84% in 2022 and then soared by 454.32% in 2023.
- Cullinan Therapeutics' Enterprise Value (Quarter) stood at -$208.9 million in 2020, then crashed by 38.85% to -$290.1 million in 2021, then tumbled by 61.1% to -$467.3 million in 2022, then tumbled by 85.75% to -$868.0 million in 2023.
- Its Enterprise Value was -$868.0 million in Q3 2023, compared to -$841.8 million in Q2 2023 and -$659.3 million in Q1 2023.